Evidence map›Paper›PMID 39528670›Full record

ArticleScientific reports2024

Integrated multiomics analysis identified comprehensive crosstalk between diverse programmed cell death patterns and novel molecular subtypes in Hepatocellular Carcinoma.

Li Chen, Yuanbo Hu, Yu Li, Bingyu Zhang, Jiale Wang, Mengmeng Deng, Jinlian Zhang, Wenyao Zhu, Hao Gu, Lingyu Zhang

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Li ChenDepartment of Blood Transfusion, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Yuanbo HuDepartment of Immunology, School of Basic Medical Sciences, Anhui Medical University, Hefei, China.
Yu LiDepartment of Laboratory Medicine, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Bingyu ZhangSchool of Public Health, China Medical University, Shenyang, China.
Jiale WangSchool of International Education, Henan University of Technology, Zhengzhou, China.
Mengmeng DengDepartment of Laboratory Medicine, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Jinlian ZhangDepartment of Pathology, the Second Affiliated Hospital of Bengbu Medical University, Benbgu, China.
Wenyao ZhuDepartment of Urology, the Central Hospital of Bengbu, Bengbu, China.
Hao GuDepartment of Immunology, School of Basic Medical Sciences, Anhui Medical University, Hefei, China. guhao@ahmu.edu.cn.
Lingyu ZhangDepartment of Laboratory Medicine, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China. lingyuzhang@zju.edu.cn.

Funding

Key Program of Anhui Provincial Department of Education 2022AH051438National Natural Science Foundation of China 82102381National Natural Science Foundation of China 82303218Natural Science Foundation of Anhui Province 2108085QH349Natural Science Foundation of Anhui Province 2308085QH285Natural Science Key Project of Bengbu Medical University 2021BYZD238
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a highly aggressive malignancy with increasing global prevalence and is one of the leading causes of cancer-related mortality in the human population. Developing robust clinical prediction models and prognostic stratification strategies is crucial for developing individualized treatment plans. A range of novel forms of programmed cell death (PCD) plays a role in the pathological progression and advancement of HCC, and in-depth study of PCD is expected to further improve the prognosis of HCC patients. Sixteen patterns (apoptosis, autophagy, anoikis, lysosome-dependent cell death, immunogenic cell death, necroptosis, ferroptosis, netosis, pyroptosis, disulfidptosis, entotic cell death, cuproptosis, parthanatos, netotic cell death, alkaliptosis, and oxeiptosis) related to PCD were collected from the literatures and used for subsequent analysis. Supervised (Elastic net, Random Forest, XgBoost, and Boruta) and unsupervised (Nonnegative Matrix Factorization, NMF) clustering algorithms were applied to develop and validate a novel classifier for the individualized management of HCC patients at the transcriptomic, proteomic and single-cell levels. Multiple machine learning algorithms developed a programmed cell death index (PCDI) comprising five robust signatures (FTL, G6PD, SLC2A1, HTRA2, and DLAT) in four independent HCC cohorts, and a higher PCDI was predictive of higher pathological grades and worse prognoses. Furthermore, a higher PCDI was found to be correlated with the presence of a repressive tumor immune microenvironment (TME), as determined through an integrated examination of bulk and single-cell transcriptome data. In addition, patients with TP53 mutation had higher PCDI in comparison with TP53 WT patients. Three HCC subtypes were identified through unsupervised clustering (NMF), exhibiting distinct prognoses and significant biological processes, among the three subtypes, PCDcluster 3 was of particular interest as it contained a large proportion of patients with high risk and low metabolic activity. Construction and evaluation of the Nomogram model was drawn based on the multivariate logistic regression analysis, and highlighted the robustness of the Nomogram model in other independent HCC cohorts. Finally, to explore the prognostic value, we also validated the frequent upregulation of DLAT in a real-world cohort of human HCC specimens by qPCR, western blot, and immunohistochemical staining (IHC). Together, our work herein comprehensively emphasized PCD-related patterns and key regulators, such as DLAT, contributed to the evolution and prognosis of tumor foci in HCC patients, and strengthened our understanding of PCD characteristics and promoted more effective risk stratification strategies.

Indexed as

ApoptosisCarcinoma, HepatocellularLiver NeoplasmsBiomarkers, TumorFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMaleMultiomicsPrognosisProteomicsTranscriptomeBiomarkers, TumorHepatocellular carcinomaIntegrated multi-omics analysisMachine learning modelMolecular subtypeProgrammed cell death

Identifiers

PMID39528670
PMCPMC11555373

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.